Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 317-320 , June 2010

Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ

  • Deborah Williamson

      Affiliations

    • Radiation Medicine Program, Princess Margaret Hospital, Department of Radiation Oncology, University of Toronto, Canada
    • ,
  • Robert Dinniwell

      Affiliations

    • Radiation Medicine Program, Princess Margaret Hospital, Department of Radiation Oncology, University of Toronto, Canada
    • ,
  • Sharon Fung

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, Toronto, Canada
    • ,
  • Melania Pintilie

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, Toronto, Canada
    • ,
  • Susan J. Done

      Affiliations

    • Laboratory Medicine Program, University Health Network, Departments of Laboratory Medicine and Pathobiology and Medical Biophysics, University of Toronto, Canada
    • ,
  • Anthony W. Fyles

      Affiliations

    • Radiation Medicine Program, Princess Margaret Hospital, Department of Radiation Oncology, University of Toronto, Canada
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Princess Margaret Hospital, 610 University Ave., Toronto, Canada M5G2M9.

Received 18 December 2009 ,Revised 18 March 2010 ,Accepted 29 March 2010.

References 

  1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546
  2. Canada H. Organized Breast Cancer Screening Programs in Canada, 2001 and 2002 Report. 2005.
  3. Dodwell D, Clements K, Lawrence G, et al. Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project. Br J Cancer. 2007;97:725–729
  4. Levi F, Te VC, Randimbison L, et al. Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer. 1997;33:903–906
  5. Kricker A, Goumas C, Armstrong B. Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology. Br J Cancer. 2004;90:1382–1385
  6. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–1441
  7. Olivotto IA, Bancej C, Goel V, et al. Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces. CMAJ. 2001;165:277–283
  8. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102
  9. Julien JP, Bijker N, Fentiman IS, et al. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528–533
  10. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–452
  11. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150
  12. Whelan T, Pignol JP, Levine M, et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. N Engl J Med. 2010;11:513–520
  13. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107
  14. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996;88:1659–1664
  15. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–970
  16. Viani GA, Stefano EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol. 2007;2:28
  17. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467
  18. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005;75:9–17
  19. Meijnen P, Oldenburg HS, Peterse JL, et al. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol. 2008;15:235–243
  20. Sahoo S, Recant WM, Jaskowiak N, et al. Defining negative margins in DCIS patients treated with breast conservation therapy: the University of Chicago experience. Breast J. 2005;11:242–247
  21. Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–1620
  22. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–3387
  23. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast – results from the Swedish randomised trial. Eur J Cancer. 2007;43:291–298
  24. Rakovitch E, Pignol JP, Hanna W, et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007;25:5591–5596
  25. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–3265

☆ This work was supported by the Phyllis Hantho Breast Cancer Research Fund and was presented in part at the San Antonio Breast Cancer Symposium, Dec. 2008.

PII: S0167-8140(10)00206-9

doi: 10.1016/j.radonc.2010.03.021

Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 317-320 , June 2010

Article Tools

* Image Usage & Resolution